Guillain-Barré syndrome, a rare and urgent medical condition, affects fewer than 20,000 people in the U.S. each year. The syndrome causes the body’s immune system to attack the nerves, leading to ...
Guillain-Barré Syndrome (GBS) is a rare but serious neurological condition that can develop suddenly, often after a common infection. While the name may not be familiar to many, understanding the ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Annexon Biosciences has announced positive topline ...
Guillain Barr The Food and Drug Administration (FDA) has granted Fast Track designation to ANX005 (Annexon Biosciences) for the treatment of Guillain-Barré Syndrome (GBS), an autoimmune disease that ...
Results showed patients treated with ANX005 30mg/kg achieved a statistically significant 2.4-fold improvement on the GBS disability score at week 8 compared with placebo. Treatment with ANX005 was ...
The American College of Physicians (ACP) issued updated vaccine practice points for physicians that advise adults aged 75 or older should receive a protein subunit Respiratory Syncytial Virus (RSV) ...
The American College of Physicians (ACP) issued updated vaccine practice points for physicians that advise adults aged 75 or older should receive a protein subunit Respiratory Syncytial Virus (RSV) ...
Dengue has spread faster than any other mosquito-borne illness, with 14 million cases reported worldwide in 2024. Dengue can rarely cause neurologic complications, including Guillain–Barré syndrome. 1 ...
Annexon (NASDAQ:ANNX) President and CEO Doug Love outlined the company's late-stage pipeline and regulatory plans during a ...
KYOTO, Japan — Eculizumab (Soliris, Alexion Pharmaceuticals) is safe for the treatment of patients with severe Guillain-Barré syndrome (GBS), a new phase 2 study shows. However, although more patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results